Jona Hattangadi-Gluth

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Jona Hattangadi-Gluth sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting early-phase tilt upper half by trial count

Jona Hattangadi-Gluth: 2 sponsored US clinical trials, 2 recruiting.

Jona Hattangadi-Gluth sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Brain Tumor, with 1 trials.

Mid-pack sponsor footprint

Jona Hattangadi-Gluth is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Jona Hattangadi-Gluth pipeline

2 recruiting of 2 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Primary Brain Tumor (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Jona Hattangadi-Gluth: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Jona Hattangadi-Gluth sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Jona Hattangadi-Gluth1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Jona Hattangadi-Gluth sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Jona Hattangadi-Gluth sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Jona Hattangadi-Gluth page

2 registered trials is a research-attention snapshot, not an endorsement of Jona Hattangadi-Gluth or any single study.

  • 2 of Jona Hattangadi-Gluth's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Primary Brain Tumor is the condition Jona Hattangadi-Gluth studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Brain Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Jona Hattangadi-Gluth pipeline card: 2 registered trials from official public datasets.Report a data error.